[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"obesity--overweight\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:obesity--overweight":651},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,142,0,25,[9,45,72,100,121,147,180,209,232,258,286,303,324,350,380,399,419,455,475,494,512,543,581,606,626],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100054247",false,"NCT07699445","The Effects of Lumateperone on Obesity and Physiologic Aging and Their Association With Antidepressant Response in Bipolar Depression","The Effects of Lumateperone on Obesity and Physiologic Aging and Their Correlation With Antidepressant Response in Bipolar Depression","Inclusion Criteria:\n\n1. Aged 18 to 65 years.\n2. Meets DSM-V criteria for Bipolar I Disorder -Depressed without psychosis as confirmed by a semi-structured clinical interview that includes the Mini International Neuropsychiatric Interview.\n3. Current episode at least 4 weeks in duration but not longer than 12 months.\n4. Depression score \\> 20 on the Montgomery Asberg Depression Rating Scale (MADRS).\n5. BMI \\> 30\n6. Capable of providing informed consent.\n\nExclusion Criteria:\n\n1. Meets DSM-V criteria for Schizophrenia, Schizoaffective disorder, or has significant mood-incongruent psychotic symptoms.\n2. Young Mania Rating Scale score \\>12.\n3. Meets DSM-V criteria for rapid cycling.\n4. Co-Morbid psychiatric illness, other than generalized anxiety and specific phobias, that in the opinion of the investigator is severe enough that it would likely interfere with the interpretation of changes in the subject's mood state.\n5. Meets DSM-V criteria for an active substance use disorder within the past month.\n6. Active medical condition that in the opinion of the investigator would contribute to the subject's depressed mood (e.g. hypothyroidism).\n7. Significant risk of suicide or self -harm as assessed by clinical interview and the Columbia Suicide Severity Rating Scale (C-SSRS).\n8. Significant risk of harm to others as assessed by clinical interview.\n9. Pregnancy, or, in women of child-bearing potential, an unwillingness to use an accepted method of birth control for the duration of the study.\n10. Current or prior treatment with lumateperone.\n11. Moderate or severe hepatic impairment.\n12. Current treatment with strong or moderate CYP3A4 inhibitors or CYP3A4 inducers.\n13. History of seizure disorder.\n14. Significant cardiovascular or cerebrovascular disease that, in the opinion of the investigator, would increase study risk.\n15. Dementia-related psychosis.\n16. Known hypersensitivity or allergy to lumateperone or any of its components.","ALL","18 Years","65 Years",{"count":7,"type":20},"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","This research study examines how a medication called lumateperone may affect mood symptoms, and inflammation in adults with bipolar disorder over approximately 6 weeks. An MRI scan to calculate biological age of the brain will also be obtained at the start of the study.",[26,27],"Bipolar Depression Depressed Phase","Obesity & Overweight",[29,30,31],"Bipolar disorder","Depression","obesity","NOT_YET_RECRUITING","2026-07-07",{"date":35,"type":36},"2026-07-13","ACTUAL",{"date":38,"type":20},"2026-07-31",{"date":40,"type":20},"2028-07-31",{"name":42,"class":43},"Massachusetts General Hospital","OTHER",1,{"id":46,"slug":4,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":44},"100054270","NCT07698145","Changes in Body Composition Including Muscle With Anti-Obesity Medications, Both With and Without Exercise","M3-E","Inclusion Criteria:\n\n* Both males and females of all race\u002Fethnic groups are eligible for participation in this study.\n* 18 to \\\u003C65 years of age.\n* Newly prescribed FDA-approved obesity manage medication that can include Tirzepatide, Semaglutide, or up to 4 additional next-generation obesity management medications (will receive DSMB approval prior to inclusion), approval for treatment (pharmacy, insurance, etc.), and the participant agreeing to start this treatment and continue treatment for at least 6 months (the participant will be recruited prior to this medication being initiated).\n* Body mass index (BMI) of \\>=27.0 kg\u002Fm2 with at least one weight-related complication (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease) provided it does not compromise the ability to safely complete the screening or outcome measures or to engage in the prescribed exercise interventions), or \\>=30 kg\u002Fm2 without weight-related complications. We will not limit enrollment based on an upper BMI level provided that the participant meets the other eligibility requirements. However, the participant will be excluded if they exceed the weight or size limits of the dual-energy x-ray absorptiometry (DXA) system that is used to assess body composition or the MRI that is used to assess muscle quality.\n* Ability to provide informed consent prior to participation in this study.\n* Clearance from the study physician for meeting all eligibility criteria for this study.\n\nExclusion Criteria:\n\n* Type 2 diabetes.\n* Report moderate-to-vigorous exercise for \\>60 min\u002Fweek, and \\>1 day\u002Fweek of structured cardiovascular or resistance exercise over the past 3 months.\n* Report sustained weight loss of \\>=3% in the past 3 months.\n* History of metabolic\u002Fbariatric surgery.\n* Females who are pregnant or breastfeeding or reporting a planned pregnancy during the study period.\n* Report a current medical condition or treatment for a medical condition that could affect body weight or contradict engagement in any aspect of the outcome measures or interventions.\n* History of muscle conditions that may impact the quality of muscle or response to the study interventions (e.g., myopathy, muscular dystrophy, rhabdomyolysis, etc.).\n* Contraindications to MRI (e.g., metal implants that are not MRI safe, etc.). NOTE: Participants who are otherwise eligible other than being contraindicated for the MRI scan will be eligible and the MRI scan will not be performed as a research procedure.\n* Current congestive heart failure, angina, uncontrolled arrhythmia, symptoms indicative of an increased acute risk for a cardiovascular event, prior myocardial infarction or history of cardiomyopathy, coronary artery bypass grafting or angioplasty, conditions requiring chronic anticoagulation (i.e., recent or recurrent DVT).\n* Resting systolic blood pressure of \\>=160 mmHg or resting diastolic blood pressure of \\>=100 mmHg. If medicated for blood pressure control, the medication dose needs to be stable for \\>=6 months.\n* Eating disorders that would contraindicate weight loss or physical activity.\n* Alcohol or substance abuse.\n* Current psychological condition that is untreated, hospitalization for a psychological condition within the past 12 months, or not being on a stable dose of treatment for at least 6 months.\n* Report plans to relocate to a location not accessible to the study site or having employment, personal, or travel commitments that prohibit attendance at scheduled intervention sessions or assessments.","64 Years",{"count":53,"type":20},198,[55],"NA","The goal of this clinical trial is to learn whether adding either cardiovascular exercise or resistance exercise to pharmacotherapy treatment for obesity improves the retention of lean mass compared to pharmacotherapy alone in adults with overweight or obesity who are prescribed pharmacotherapy for obesity treatment by their personal physician. It will also provide information about whether either form of exercise added to pharmacotherapy for obesity treatment has additional benefits on other health and fitness measurements. The main questions it aims to answer are:\n\n* Is there a difference in the change in total lean body mass between pharmacotherapy alone and either pharmacotherapy plus cardiovascular exercise or pharmacotherapy plus resistance exercise?\n* Is there a difference in the change in muscle mass between the intervention conditions (pharmacotherapy alone, pharmacotherapy plus cardiovascular exercise, pharmacotherapy plus resistance exercise)?\n* Is there a difference in the change in muscle quality between the intervention conditions (pharmacotherapy alone, pharmacotherapy plus cardiovascular exercise, pharmacotherapy plus resistance exercise)?\n* Is there a difference in the change in body weight between the intervention conditions (pharmacotherapy alone, pharmacotherapy plus cardiovascular exercise, pharmacotherapy plus resistance exercise)?\n* Is there a difference in the change in body composition (fat mass, fat mass distribution) between the intervention conditions (pharmacotherapy alone, pharmacotherapy plus cardiovascular exercise, pharmacotherapy plus resistance exercise)?\n* Is there a difference in the change in cardiorespiratory fitness between the intervention conditions (pharmacotherapy alone, pharmacotherapy plus cardiovascular exercise, pharmacotherapy plus resistance exercise)?\n* Is there a difference in the change in muscle strength between the intervention conditions (pharmacotherapy alone, pharmacotherapy plus cardiovascular exercise, pharmacotherapy plus resistance exercise)?\n* Is there a difference in the change in physical function between the intervention conditions (pharmacotherapy alone, pharmacotherapy plus cardiovascular exercise, pharmacotherapy plus resistance exercise)?\n* Is there a difference in the change in bone mineral density between the intervention conditions (pharmacotherapy alone, pharmacotherapy plus cardiovascular exercise, pharmacotherapy plus resistance exercise)?\n* Is there a difference in the change in bone biomarkers between the intervention conditions (pharmacotherapy alone, pharmacotherapy plus cardiovascular exercise, pharmacotherapy plus resistance exercise)?\n* Is there a difference in the change in resting blood pressure between the intervention conditions (pharmacotherapy alone, pharmacotherapy plus cardiovascular exercise, pharmacotherapy plus resistance exercise)?\n* Is there a difference in the change in energy intake between the intervention conditions (pharmacotherapy alone, pharmacotherapy plus cardiovascular exercise, pharmacotherapy plus resistance exercise)?\n* Is there a difference in the change in physical activity between the intervention conditions (pharmacotherapy alone, pharmacotherapy plus cardiovascular exercise, pharmacotherapy plus resistance exercise)?\n* Is there an effect of sex, race\u002Fethnicity, age, menopausal status, obesity management medication type, or other demographic characteristics on the outcomes that are being measured.\n* What is the extent to which the retention of lean body mass or muscle mass mediates the effect of exercise on weight changes.\n\nParticipants will:\n\n* Initiate and continue throughout the study period an eligible obesity management medication that is prescribed by their healthcare provider, and to report their adherence to this medication to the investigators.\n* Participant in this study for a period of 6-8 months to complete outcome assessments that occur at baseline and at the conclusion of 6 months of the intervention period, and monitoring visits that occur at weeks 3, 6, 9, 12, 15, 18, and 21.\n* If attend 3 supervised exercise sessions per week if assigned to either the cardiovascular exercise intervention or the resistance training intervention for a period of 24 weeks.",[27],[59,31,60,61,62,63],"overweight","exercise","physical activity","pharmacotherapy","body composition","2026-07-06",{"date":35,"type":36},{"date":67,"type":20},"2026-07",{"date":69,"type":20},"2030-03",{"name":71,"class":43},"University of Kansas Medical Center",{"id":73,"slug":4,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":99},"100627312","NCT07446998","Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss","PLATEAU: Phase 2b Proof-of-Concept Study to Evaluate the Effect on Total Body Weight, Physical Function and Safety of Enobosarm in Patients Treated With Semaglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, for Weight Reduction","PLATEAU","Inclusion Criteria:\n\n* Subjects accepted for this study must:\n\n  1. Provide informed consent from the subject or the subject's legally authorized representative\n  2. Be able to communicate effectively with the study personnel\n  3. Be ≥65 years of age at the time of screening\n  4. For Female Subjects Menopausal status\n\nBe postmenopausal as defined by either:\n\n* one year or more of amenorrhea\n* surgical menopause with bilateral oophorectomy\n* Be premenopausal or perimenopausal with a negative pregnancy test.\n* If subject is of child bearing potential, the subject must agree to use acceptable methods of contraception: If female study participant could become pregnant, use acceptable methods of contraception from the time of the first administration of study medication until 30 days following administration of the last dose of study medication. Acceptable methods of contraception are as follows: Condom with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fsuppository \\[i.e., barrier method of contraception\\], surgical sterilization of male partner (vasectomy with documentation of azoospermia) and a barrier method {condom used with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fsuppository}, oral contraceptives (combination estrogen\u002Fprogesterone pills), injectable progesterone or subdermal implants and a barrier method (condom used with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fsuppository)\n\nIf female study participant has undergone documented tubal ligation (female sterilization), a barrier method (condom used with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fsuppository) should also be used\n\nIf female study participant has undergone documented placement of an intrauterine device (IUD) or intrauterine system (IUS), a barrier method (condom with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fsuppository) should also be used For Male Subjects\n\nSubject must agree to use acceptable methods of contraception:\n\nIf the study subject's partner could become pregnant, use acceptable methods of contraception from the time of the first administration of study medication until 30 days following administration of the last dose of study medication. Acceptable methods of contraception are as follows: Condom with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fsuppository \\[i.e., barrier method of contraception\\], surgical sterilization (vasectomy with documentation of azoospermia) and a barrier method {condom used with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fsuppository}, the female partner uses oral contraceptives (combination estrogen\u002Fprogesterone pills), injectable progesterone or subdermal implants and a barrier method (condom used with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fsuppository)\n\nIf female partner of a study subject has undergone documented tubal ligation (female sterilization), a barrier method (condom used with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fsuppository) should also be used\n\nIf female partner of a study subject has undergone documented placement of an intrauterine device (IUD) or intrauterine system (IUS), a barrier method (condom with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fsuppository) should also be used\n\nFemale partner is menopausal as defined above\n\n5\\. Medically indicated for use of semaglutide for weight reduction 6. Have BMI ≥35 7. Consents to continue treatment with semaglutide for up to 476 days under this protocol. 8. Subject is willing to comply with the requirements of the protocol through the end of the study 9. The patient is able to swallow oral medications 10.The patient is able to complete the physical function (stair climb) assessment 11.Maximum weight at screening of 350lbs as per DXA requirements\n\nExclusion Criteria\n\nAny of the following conditions are cause for exclusion from the study:\n\n1. Known hypersensitivity or allergy to enobosarm or a GLP-1 receptor agonist\n2. Estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73 m2 as measured using the chronic kidney disease-epidemiology collaboration (CKD-EPI) calculation (patients with mild and moderate renal failure are not excluded from participation in this study)\n3. Treatment with any investigational product within \\\u003C 5 half-lives for each individual investigational product OR within 30 days prior to randomization\n4. Major surgery (the surgery poses a significant risk to patients life and requires general anesthesia) within 30 days prior to randomization\n5. Planned major surgery during the course of the study or any cosmetic surgery potentially impacting body composition, e.g., liposuction, implants, or removal of any current implants\n6. Testosterone, methyltestosterone, oxandrolone (Oxandrin®), oxymetholone, danazol, fluoxymesterone (Halotestin®), testosterone-like agents (such as dehydroepiandrosterone, androstenedione, and other androgenic compounds, including herbals), myostatin inhibitors, apelin receptor agonists, or antiandrogens (flutamide, bicalutamide, abiraterone, enzalutamide, apalutamide, or darolutamide).\n\n   Previous therapy with testosterone and testosterone-like agents is acceptable with a 30-day washout (if previous testosterone therapy was long term depot within the past 6 months, the site should contact the Medical Monitor) or any other androgenic agent.\n7. An abnormal ECG result which, based on the investigator's clinical judgment, would place the subject at increased medical risk. A QTcF \\>450 ms for males and \\>460 ms for females is also exclusionary from this protocol.\n8. Concurrently participating in any other interventional or treatment clinical trial.\n9. Pre-existing liver disease (hepatitis B, uncontrolled hepatitis A, hepatitis C, autoimmune hepatitis, liver cancer, alcohol-associated cirrhosis, alcohol-associated hepatitis, alcohol-associated fatty liver)\n10. Baseline ALT or AST \\>3x upper limit of normal\n11. Baseline total bilirubin levels \\>upper limit of normal (except in cases of Gilbert's Syndrome)\n12. History of acute pancreatitis within one year of screening or history of chronic pancreatitis\n13. Severe gastrointestinal disease, including gastroparesis\n14. Major depressive disorder diagnosed within 2 years prior to screening (NOTE: a diagnosis of major depressive disorder ≥2 years prior to screening that is stably managed \\[with or without pharmacological intervention\\] without additional exclusionary history are not excluded from the study), history of other severe psychiatric disorder, including schizophrenia and bipolar disorder, any lifetime history of suicide attempt, or with suicidal ideation or behavior within 1 month prior to screening.\n15. Patient Health Questionnaire score \\>15 or any suicidal ideation of type 4 or type 5 on the Columbia-Suicide Severity Rating Scale\n16. Monogenic or syndrome obesity, and endocrine causes of obesity (such as untreated hypothyroidism or Cushing's syndrome), and obesity caused by medications that cause weight gain\n17. Prior bariatric surgery or weight loss devices unless removed for ≥1 year prior to screening for this study.\n18. Diagnosis of diabetes requiring current use of any antidiabetic drug or HbA1c ≥6.5%\n\n    Note: Metabolic syndrome is not an exclusion, even if managed with an anti-diabetic drug such as metformin or an SGLT2 inhibitor. A diagnosis of prediabetes or impaired glucose tolerance managed with antidiabetic medication or non-pharmacologic approaches (e.g., diet and exercise) is not an exclusion as long as other study criteria are met and the patient has not progressed to a diagnosis of diabetes.\n19. Creatine kinase \\>1.5x ULN\n20. Any condition that is exclusionary for use of semaglutide (generally WEGOVY) in the patient. See the WEGOVY Prescribing Information. The following contraindications are listed in the WEGOVY prescribing information:\n\n    1. Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2\n    2. Known hypersensitivity to semaglutide or any of the excipients in WEGOVY.\n21. Subjects with active or untreated malignancy within 5 years of screening (NOTE:\n\n    treated non-melanoma skin cancers are allowable).\n22. Male subjects with a lifetime history of malignant prostate disease, such as prostate cancer.\n23. Male subjects with a PSA ≥4 ng\u002FmL\n24. Patients with prior tendon rupture or those taking concomitant medications that increase the risk of tendon rupture (e.g., fluroquinoline antibiotics, bempedoic acid, or chronic use of systemic corticosteroids).\n25. Uncontrolled hypertension (systolic blood pressure ≥160 mmHg and\u002For diastolic blood pressure ≥100 mmHg). NOTE: blood pressure may be retested as per the investigator criteria as needed.\n26. Patients with a resting heart rate ≥100 beats per minute. NOTE: heart rate may be retested as per the investigator criteria as needed.\n27. Patients that have received a GLP-1 Receptor Agonist (e.g., semaglutide) or a GIP\u002FGLP-1 Receptor agonist (e.g., tirzepatide) within 12 months of Screening.\n28. Patients that wear foreign objects, at the discretion of the DXA technician, that cannot be removed at the time of DXA that could cause artifacts and decrease accuracy of exam, such as waist beads (e.g., for religious purposes).","100 Years",{"count":81,"type":20},200,[83],"PHASE2","The primary objective of this study is to assess the effect of enobosarm on total body weight",[27,86,87],"Mobility Disability","HOMA-IR","RECRUITING","2026-06-30",{"date":91,"type":36},"2026-07-01",{"date":93,"type":36},"2026-03-26",{"date":95,"type":20},"2027-12",{"name":97,"class":98},"Veru Inc.","INDUSTRY",14,{"id":101,"slug":4,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":105,"sex":16,"minAge":17,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":21,"phases":109,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":44},"100644864","NCT07675148","Cooking Classes as a Family-based Intervention for Weight Reduction: Effects on Dietary Quality and Weight Management in Abu Dhabi (United Arab Emirates)","Inclusion Criteria:\n\n* Emirati\n* Based in Abu Dhabi\n* Home cooked meals prepared by full-time home cooks who are certified in the ICCA Culinary Medicine course (post 4 weeks cooking training)\n* Certified home cooks are residing with participant during the training and intervention\n* Aged between 18 years and 60 years\n* BMI between 28-40 kg\u002Fm2\n* Participant and cooks being able to provide informed consent\n\nExclusion Criteria:\n\n* Body weight exceeding 220 kilograms at the time of recruitment\n* Undergoing treatment for serious illnesses (active cancer), planned for surgery, interventional management, and immunomodulation\n* Undergone surgery within 3 months prior to study recruitment, including bariatric surgery\n* Enrolled in other lifestyle intervention programs",true,"60 Years",{"count":108,"type":20},500,[55],"The goal of this quasi-experimental interventional study is to learn if healthy cooking classes for home cooks can improve weight management and dietary quality among Emirati adults with overweight or obesity living in Abu Dhabi. The main questions it aims to answer are:\n\n* Does participation in the culinary medicine program reduce body weight over time?\n* Does the intervention improve diet quality and increase compliance with healthy home-cooked meals?\n* Does the intervention improve health measures such as waist circumference, body fat percentage, blood pressure, and heart rate?\n* What are the experiences and satisfaction levels of participating family members and trained home cooks?\n\nParticipants will:\n\n* Enroll in a 3-month family-based nutrition intervention program\n* Receive meals prepared by home cooks trained in culinary medicine through the ICCA program\n* Complete assessments before the intervention, during the intervention, and 3 months after completion\n* Undergo measurements including weight, waist circumference, body fat percentage, blood pressure, and heart rate\n* Complete questionnaires about diet quality, meal habits, and overall program experience",[27,112],"Culinary Medicine","2026-06-29",{"date":89,"type":36},{"date":116,"type":36},"2025-10-08",{"date":118,"type":20},"2026-10-31",{"name":120,"class":43},"Institute for Healthier Living Abu Dhabi",{"id":122,"slug":4,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":21,"phases":130,"briefSummary":131,"conditions":132,"keywords":135,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":140,"startDateStruct":141,"completionDateStruct":142,"leadSponsor":144,"locationsCount":146},"100639897","NCT07599072","PREdiabetes GLycemic Impact and Data Evaluation","Evaluation of the Impact of Continuous Glucose Monitoring (CGM) Systems on Glycemic Control in People With Prediabetes: Postmarketing Clinical Study","PRE-GLIDE","Inclusion Criteria:\n\n* Age of 18 years and older.\n* Presence of prediabetes diagnosed according to criteria of the American Diabetes Association\n* Persons who treated with diet and exercise alone or metformin on a stabilized dose for at least 3 months before the study;\n* Ability to comply with protocol requirements and maintain a patient diary.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Presence of type 1 or type 2 diabetes;\n* Decompensated liver or kidney diseases (GFR \\\u003C 45 ml\u002Fmin\u002F1. 73 m²);\n* Active cardiovascular diseases within 12 months of Visit 1, such as myocardial infarction, clinically significant arrhythmia, unstable angina, coronary artery bypass surgery, or angioplasty; or are expected to require coronary artery bypass surgery or angioplasty during the course of the study;\n* Endocrine disorders (e.g., Itsenko-Cushing syndrome, acromegaly) that affect glycemia;\n* Pregnancy or lactation;\n* Mental or cognitive impairments that would interfere with study participation;\n* Daily use of any form of steroid medication (oral, inhaled, injected) within the last 3 months;\n* Recent use of any CGM within the last 12 months;\n* Known allergy to sensor materials;\n* Has evidence of current abuse of drugs or alcohol or a history of abuse that, in the investigator's opinion, would cause the individual to be noncompliant;\n* Participation in another clinical study within the last 3 months.",{"count":129,"type":20},80,[55],"This prospective, randomized controlled trial evaluates whether real-time continuous glucose monitoring (CGM) improves glycemic control and lifestyle adherence in adults with prediabetes compared to conventional self-monitoring methods over a 3-month period. By analyzing metabolic markers and behavioral data, the study aims to determine the effectiveness of 24-hour monitoring as a personalized tool that increases patient adherence to lifestyle changes compared to conventional SMBG methods.",[133,27,134],"Pre Diabetic","Insulin Resistance",[136,31,137,138,139],"prediabetes","continuous glucose monitoring","insulin resistance","traditional glycemia self-monitoring",{"date":89,"type":36},{"date":91,"type":20},{"date":143,"type":20},"2027-06-30",{"name":145,"class":43},"Nazarii Kobyliak",3,{"id":148,"slug":4,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":16,"minAge":152,"maxAge":153,"enrollmentInfo":154,"targetDuration":4,"studyType":156,"phases":4,"briefSummary":157,"conditions":158,"keywords":160,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":172,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":179},"100627087","NCT07444073","Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock","Inclusion Criteria\n\n* Adults aged 40-89 years, who are newly enrolled in the NOVI OP+ weight management program.\n* BMI of ≥ 30 kg\u002Fm2 (obesity); OR\n* BMI of ≥ 27 kg\u002Fm2 to \\\u003C 30 kg\u002Fm2 (overweight) in the presence of at least one weight-related comorbid condition e.g. dysglycemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease.\n\nExclusion Criteria\n\n* Pregnancy or lactation.\n* Non-ambulatory status, total blindness, complete hearing loss, or inability to speak.\n* Medical history of, or self-reported, psychiatric illness, congenital or irreversible neurodegenerative diseases, cognitive impairment, or eating disorders that may affect adherence or assessment outcomes.\n* On GLP-1 RA, sulfonylurea or insulin medications for the past 3 months.\n* Active cancer on chemotherapy or immunotherapy.\n* Known hypersensitivity or contraindications to GLP-1 RAs.\n* Any condition, in the opinion of the attending clinician, that would jeopardize participant safety or interfere with study compliance.","40 Years","89 Years",{"count":155,"type":20},440,"OBSERVATIONAL","This study examines whether routine treatment with semaglutide or tirzepatide, prescribed with lifestyle coaching in a real-world weight-management program, is associated with changes in biological age measured by the LinAge2 clinical aging clock over 6 months.",[159,27],"Aging",[161,162,163,164,165,166,167,168,169,170,171],"LinAge2","Biological Age","GLP-1 Receptor Agonist","Semaglutide","Tirzepatide","Weight Management Program","Lifestyle","Real-World Evidence","Cardiometabolic Biomarkers","Body Composition","Prospective Cohort",{"date":91,"type":36},{"date":174,"type":20},"2026-06-01",{"date":176,"type":20},"2027-12-31",{"name":178,"class":43},"National University of Singapore",2,{"id":181,"slug":4,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":186,"targetDuration":4,"studyType":21,"phases":188,"briefSummary":189,"conditions":190,"keywords":195,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":179},"100644753","NCT07672821","Time-Restricted Eating After Bariatric Surgery","Comparison of Time-Restricted Intermittent Fasting Diet in Individuals With and Without Bariatric Surgery","Inclusion Criteria:\n\n* Adults aged 18-65 years with obesity who have not undergone bariatric surgery\n* Adults aged 18-65 years with obesity who have undergone bariatric surgery and experienced insufficient weight loss (IWL) within 18 months post-surgery, -defined as %EWL \\\u003C50% at 18 months\n* Adults aged 18-65 years with obesity who have undergone bariatric surgery and experienced weight regain (WR), defined as \\>25% increase in %EWL from the lowest recorded weight\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding individuals\n* Acute illness, active infection, or comorbid conditions limiting treatment efficacy and safety, including: cancer, type 1 diabetes, renal or hepatic failure, recent stroke or myocardial infarction, nephrolithiasis, drug or alcohol abuse, eating disorders, severe depression or other psychiatric disorders, inflammatory bowel disease (IBD), neoplasia, arrhythmic heart disease, heart failure, respiratory failure, or corticosteroid therapy\n* Professional athletes",{"count":187,"type":20},40,[55],"This study aims to compare the effects of time-restricted eating (TRE, 16\u002F8) in adults with obesity who have and have not undergone bariatric surgery (BS). The study will include adults aged 18-65 years: those with obesity who have not undergone BS, and those who have experienced insufficient weight loss (IWL) or weight regain (WR) following BS. Both groups will follow a 16:8 time-restricted eating protocol for 6 weeks, with an 8-hour eating window recommended between 10:00 AM and 6:00 PM, though participants may adjust to other 16-hour fasting windows. Participants will be evaluated before and after the intervention in terms of anthropometric measurements, biochemical parameters, and dietary habits. The study is being conducted at a private hospital in Bursa, Turkey, and is planned to be completed with a total of 40 participants (20 per group).",[27,191,192,193,194],"Bariatric Surgery","Weight Regain","Weight Regain Post Bariatric Surgery","Time Restricted Feeding",[196,197,191,198,192,199,200],"Time-Restricted Eating","Intermittent Fasting","Obesity","Anthropometric Measurements","Nutritional Assessment","2026-06-26",{"date":113,"type":36},{"date":204,"type":36},"2025-07-12",{"date":206,"type":20},"2026-07-12",{"name":208,"class":43},"Medipol University",{"id":210,"slug":4,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":16,"minAge":215,"maxAge":216,"enrollmentInfo":217,"targetDuration":4,"studyType":21,"phases":219,"briefSummary":220,"conditions":221,"keywords":223,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":225,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":44},"100635745","NCT07556679","PLAY2CONTROL Study","Active Video Games and Their Effect on Weight Loss and HgbA1c in Patients With Obesity and Type 2 Diabetes Mellitus","Inclusion Criteria:\n\n* Patients followed at the University of Miami Pediatric Endocrinology Clinic\n* Must have a diagnosis of Obesity (BMI \\>= 95th percentile) and Type 2 Diabetes Mellitus (Hemoglobin A1c \\> 6.5%)\n* Children and teenagers, 5-18 years old\n* Young adults 19-21 years old\n\nExclusion Criteria:\n\n* Patients who have conditions preventing physical activity (such as physical limitations)\n* Patients without Televisions at home\n* Pregnant females\n* Patients in juvenile detention or prison\n* Adults unable to consent","5 Years","21 Years",{"count":218,"type":20},30,[55],"The purpose of this study is to assess the impact of active video gaming participation in otherwise sedentary patients with obesity and Type 2 diabetes mellitus. The study will assess changes in sedentary time, activity level and changes in weight and Hemoglobin A1c, as well as other complications related to obesity that is monitored in clinic.",[222,27],"Type 2 Diabetes",[224],"Pediatrics",{"date":91,"type":36},{"date":227,"type":20},"2026-08",{"date":229,"type":20},"2027-08",{"name":231,"class":43},"University of Miami",{"id":233,"slug":4,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":105,"sex":239,"minAge":240,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":21,"phases":243,"briefSummary":244,"conditions":245,"keywords":248,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":252,"startDateStruct":253,"completionDateStruct":254,"leadSponsor":256,"locationsCount":44},"100619937","NCT07351110","Improving Cervical Cancer Prevention Among Women Living With Chronic Conditions.","Improving Cervical Cancer Prevention Among Women Living With Chronic Conditions. Aim 3: Assess the Feasibility and Acceptability of the PINPOINT Intervention.","PINPOINT","Inclusion Criteria:\n\nThe following eligibility criteria will be used to determine inclusion into the study:\n\n1. Using the American Cancer Society (ACS) screening recommendations, adults aged over the age of 25 will be eligible\n2. Active UF Internal Medicine patient and has had an appointment in the last 2 months.\n3. Assigned sex at birth is female\n4. Have Obesity or Type 2 Diabetes\n5. Not currently pregnant (self-report)\n6. Have not given birth in the prior 12 weeks\n7. No previous history of cervical cancer\n8. No previous history of a hysterectomy\n9. Have not undergone cancer screening in the past 3 years or more\n10. Reside in the UFHCI Catchment Area (Alachua, Baker, Bradford, Citrus, Clay, Columbia, Dixie, Gadsden, Gilchrist, Hamilton, Jefferson, Lafayette, Lake, Leon, Levy, Madison, Marion, Putnam, Sumter, Suwannee, Taylor, UnioF1n, or Wakulla County).\n11. Have a mobile phone or access to a mobile phone that can be used to receive messages, or a valid email address.\n12. Are not currently scheduled to receive cervical cancer screening via clinician sampling (pap smear).\n\nExclusion Criteria:\n\n* Previous history of cervical cancer\n* Total hysterectomy\n* Pregnant","FEMALE","25 Years",{"count":242,"type":20},20,[55],"Our overarching goal is to adapt and test the PINPOINT intervention -PatIent Navigation for the Prevention of CervIcal CaNcer inTervention. We will test the PINPOINT intervention among patients with high-risk profiles for cervical cancer who do not meet the recommended screening for cervical cancer.",[246,247,27],"Diabetes","Cervical Cancer (Early Detection)",[249,250,251],"cervical cancer screening","self-collection","self-sampling",{"date":89,"type":36},{"date":89,"type":20},{"date":255,"type":20},"2027-03-24",{"name":257,"class":43},"University of Florida",{"id":259,"slug":4,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":105,"sex":16,"minAge":17,"maxAge":264,"enrollmentInfo":265,"targetDuration":4,"studyType":21,"phases":267,"briefSummary":269,"conditions":270,"keywords":272,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":44},"100644845","NCT07675590","A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects","A Single Center, Multiple Dose, Randomized, Placebo-controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects","Inclusion Criteria:\n\n1. Subjects aged 18-70 years, both genders.\n2. Healthy as determined by the Investigator, based on history, medical examination, vital signs, laboratory tests, cardiac monitoring and respiratory function. History must comply with the following:\n\n   1. Absence of clinically significant illness or surgery within the preceding 12 weeks.\n   2. Absence of clinically significant history of neurological, endocrine, cardiovascular, pulmonary, hematological, immunologic, psychiatric, gastrointestinal, renal, hepatic, and\u002For metabolic disease.\n3. Male subjects with female partners of childbearing potential must agree to utilize condoms for the duration of the study.\n4. Female subjects of child-bearing potential with negative urine pregnancy tests and who agree to use double-barrier contraception during the study. The primary contraception may be oral contraceptives, hormonal implant or hormonal or non-hormonal intrauterine device, and the secondary (barrier) method of contraception with condom and\u002For with spermicide.\n5. Female subjects of non-child-bearing potential (i.e. bilateral tubal ligation (BTL), bilateral tubal occlusion (BTO), bilateral salpingectomy, hysterectomy, partial hysterectomy, bilateral oophorectomy, or postmenopausal, defined as no menses for 12 months without an alternative medical cause).\n6. Body mass index (BMI) 25 - 34.9 kg\u002Fm2\n7. HbA1c \\\u003C6.5%\n8. Willingness to fully comply with protocol.\n\nExclusion Criteria:\n\n1. History of excessive alcohol use (defined as \\>21 drinks per week for males and \\>14 drinks per week for females), recreational drug use or drugs of abuse within the past three months, or failure on urinary drug screen.\n2. Pregnant or breastfeeding within six months of screening assessment.\n3. Substantial changes in eating habits or exercise routines within the preceding three months.\n4. Evidence of eating disorders.\n5. \\>5% weight change in the past three months.\n6. Bariatric surgery within the past five years.\n7. Significant renal impairment (eGFR \\\u003C60 mL\u002Fmin\u002F1.73m2).\n8. Liver function tests (i.e., ALT, AST, alkaline phosphatase) greater than twice the upper limit of normal upon repeated measurements.\n9. Diseases interfering with metabolism and\u002For ingestive behavior (e.g., myxedema, Cushing's disease, schizophrenia, major psychoses, unmanaged depression).\n10. Use of prescription medications during screening and duration of the trial.\n11. Use of drugs approved for the treatment of obesity.\n12. Any clinically significant abnormality following the Investigator's review of the physical examination and clinical laboratory tests.\n13. A baseline prolongation of QT\u002FQTcF interval after repeated measurements of \\>450 ms for men and \\>470 for women; a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmias or torsades de pointes, structural heart disease, or a family history of LQTS.\n14. Participation in an investigational drug trial within three months prior to dosing in the present study.","70 Years",{"count":266,"type":20},18,[268],"PHASE1","Randomized, Placebo-controlled Study to determine the safety and tolerability of multiple oral doses of TIX100 administered daily for 28 days to otherwise healthy overweight\u002Fobese subjects.",[271,27],"Health Adult Subjects",[273,274,275,276,277],"inhibitor of thioredoxin-interacting protein","TXNIP","TIX100","TIXiMED","Type 1 Diabetes","2026-06-25",{"date":89,"type":36},{"date":281,"type":20},"2026-06-22",{"date":283,"type":20},"2026-12",{"name":285,"class":98},"TIXiMED, Inc.",{"id":287,"slug":4,"hasResults":11,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":4,"eligibilityCriteria":291,"healthyVolunteers":105,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":292,"targetDuration":4,"studyType":21,"phases":294,"briefSummary":295,"conditions":296,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":298,"startDateStruct":299,"completionDateStruct":300,"leadSponsor":301,"locationsCount":44},"100633430","NCT07526584","Comparing the Effects of Front-of-Package Labeling Schemes in Indonesia","Comparing the Effects of Two Front-of-Package Labeling Schemes Among Indonesian Consumers","Inclusion Criteria:\n\n* 18 years of age or older\n* Lives in Indonesia\n* Able to read and write in Indonesian\n* Has purchased processed foods in the last month\n\nExclusion Criteria:\n\n* Less than 18 years old\n* Does not live in Indonesia\n* Not able to read and write in Indonesian\n* Has not purchased processed foods in the last month",{"count":293,"type":20},1000,[55],"The goal of this study is to examine what type of front-of-package label (FOPL) would be most effective at discouraging consumption of products high in nutrients of concern in Indonesia. The main questions this experiment aims to answer are:\n\n1. Would nutrient warning labels be more effective at discouraging consumption of products high in nutrients of concern compared to the Nutri-Level label?\n2. Would nutrient warning labels improve consumers' ability to identify unhealthy products compared to the Nutri-Level label?\n\nAdditionally, this experiment also aims to determine how should nutrient warning labels be designed to most effectively discourage consumption of products high in nutrients of concern among Indonesian consumers.",[297,27],"Nutrition",{"date":113,"type":36},{"date":67,"type":20},{"date":227,"type":20},{"name":302,"class":43},"University of North Carolina, Chapel Hill",{"id":304,"slug":4,"hasResults":11,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":308,"eligibilityCriteria":309,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":106,"enrollmentInfo":310,"targetDuration":4,"studyType":21,"phases":311,"briefSummary":312,"conditions":313,"keywords":314,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":318,"startDateStruct":319,"completionDateStruct":320,"leadSponsor":322,"locationsCount":4},"100626009","NCT07430059","Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant","A Randomized, Parallel-Group Study to Assess the Safety, Tolerability, and Pharmacokinetics of Semaglutide Implant","SLIM-1","Inclusion Criteria:\n\n* BMI between 27 and 40 kg\u002Fm2 (inclusive)\n* HbA1c \\\u003C\u002F= 6.0% and FPG \\\u003C\u002F+ 6.7 mmil\u002FL\n* eGFR \\>\u002F= 60 mL\u002Fm2\n* No significant health issues in the opinion of the Investigator that would preclude study participation, as determined by medical history and physical examination\n\nExclusion Criteria:\n\n* Type 1 or Type 2 Diabetesa\n* A clinically significant medical condition that could potentially affect study participation and\u002For personal well-being, as judged by the Investigator\n* Treatment with glucose lowering agent(s) within 3 months before Screening",{"count":242,"type":20},[268],"The study will evaluate the safety, tolerability and drug levels of a semaglutide implant placed just under the skin for a period of 4 weeks compared to 4 weekly injections of semaglutide (Wegovy) in overweight\u002Fobese participants who are otherwise healthy..",[27],[31,59,315,316,317],"semaglutide","implant","glp-1",{"date":89,"type":36},{"date":67,"type":20},{"date":321,"type":20},"2027-01",{"name":323,"class":98},"Vivani Medical, Inc",{"id":325,"slug":4,"hasResults":11,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":4,"eligibilityCriteria":329,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":330,"targetDuration":4,"studyType":21,"phases":332,"briefSummary":333,"conditions":334,"keywords":338,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":44},"100634146","NCT07535892","Scalable Behavioral Program for Weight Loss Maintenance After GLP-1 and Anti-Obesity Medication Discontinuation","Pilot Trial of a Scalable Behavioral Program for Weight Loss Maintenance After GLP-1 and Anti-Obesity Medication Discontinuation","Inclusion Criteria:\n\n* Age 18 years or older\n* Loss of ≥15% of initial body weight using anti-obesity medication\n* Discontinued anti-obesity medication within the past 4 weeks or planning to discontinue prior to randomization\n* ≤3 kg weight regain within the past 3 months\n* Willing and able to participate in a 6-month behavioral intervention, including a 10-week foundational program\n* Willing to complete study assessments at baseline, 3 months, and 6 months, including required in-person visits\n* Medical clearance for participation in moderate physical activity, dietary modification, and mind-based practices\n* Access to reliable internet for participation in virtual sessions and remote data collection\n* English fluency sufficient to complete study procedures\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Medical conditions that would preclude safe participation in physical activity, dietary changes, or mind-based practices (e.g., unstable cardiovascular disease, uncontrolled hypertension, severe orthopedic limitations, or seizure disorders not medically managed)\n* Active psychiatric conditions that would interfere with participation or safety (e.g., untreated major depression, active substance use disorder, or psychosis)\n* Pregnancy, breastfeeding, or plans to become pregnant during the study period\n* Current participation in another structured weight loss or weight maintenance program\n* Continued use of anti-obesity medication after randomization\n* Plans to initiate medications or treatments that may significantly affect body weight during the study period\n* Inability to attend required study visits or participate in virtual sessions and remote data collection\n* Any condition that, in the opinion of the investigators, would compromise participant safety or study integrity",{"count":331,"type":20},64,[55],"This study is a single-site, pilot randomized factorial trial designed to evaluate the feasibility, acceptability, participant perceptions and preliminary effects of a multi-component behavioral intervention to support weight loss maintenance following discontinuation of GLP-1 and other anti-obesity medications. The intervention includes a standardized 10-week foundational weight loss maintenance program combined with candidate support components, including medically tailored meals, YMCA membership, and a structured mind-based program. Participants will be randomized using a 2 × 2 × 2 factorial design and followed for six months. Findings from this pilot study will inform optimization of a scalable intervention for future clinical trials.",[335,336,337,27],"Weight Loss","GLP - 1","Weight Loss Maintenance",[335,339,340,341],"GLP-1","Anti-Obesity Medication","weight loss maintenance","2026-06-23",{"date":201,"type":36},{"date":345,"type":20},"2026-11-01",{"date":347,"type":20},"2029-07-31",{"name":349,"class":43},"University of Alabama at Birmingham",{"id":351,"slug":4,"hasResults":11,"nctId":352,"briefTitle":353,"officialTitle":353,"acronym":4,"eligibilityCriteria":354,"healthyVolunteers":105,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":355,"targetDuration":4,"studyType":21,"phases":357,"briefSummary":358,"conditions":359,"keywords":361,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":44},"100610397","NCT07227051","Optimizing Self-Monitoring Feedback Delivery for the Treatment of Overweight and Obesity","Inclusion Criteria:\n\n* Age greater than or equal to 18 years\n* BMI greater than or equal to 25.0 kg\u002Fm2\n* Weight less than or equal to 175 kg (due to scale limit)\n* Own a smartphone compatible with Fitbit (e.g., an Apple iPhone running iOS 16.4 or higher or Android smartphone running Android 11 or higher) with a cellular and data plan\n\nExclusion Criteria:\n\n* Weight greater than 175 kg (due to a weight limit of the study-provided scale)\n* Smartphone device owned deemed incompatible with the Fitbit App\n* History of bariatric surgery or plans to obtain bariatric surgery during the study period\n* Current use of weight loss medications, or use of weight loss medications in the 6 months prior to initial pre-screening\n* Currently participating in a weight-loss program\n* Weight loss of greater than or equal to 10 lbs in the 6 months prior to initial pre-screening\n* Physical limitations that prevent walking at a brisk pace for at least 10 minutes without stopping\n* Use of a pacemaker or other implanted medical device\n* Currently pregnant\n* Currently breastfeeding\n* Less than 1-year post-partum\n* Plans to become pregnant within the study period\n* Lack of written confirmation that the potential participant has discussed study participation with their physician if they have been diagnosed with diabetes, hypertension, or has have a history of coronary heart disease\n* One or more study participants living in the household (enrollment limited to one participant per household)\n* Medical conditions that contraindicate weight loss or prevent completion of the study (e.g., current diagnosis of cancer or terminal illness, dementia, etc.)\n* Recent (in the past 6 months) changes in medications that affect weight\n* Self-reported eating disorder within past 5 years\n* Unable to complete the 17-week study (due to plans to relocate during the study period, etc.)\n* Unable or unwilling to provide informed consent\n* Unable to read English at the 5th grade level\n* Unwilling to accept random assignment\n* Unable or unwilling to download the study smartphone application, wear the physical activity monitor, or use the study e-scale\n* Failure to complete baseline assessment measures\n* Failure to complete at least 4 out of 6 days of self-monitoring dietary and weight self-monitoring during the behavioral run-in period\n* Any other condition(s) which, in the opinion of the Principal Investigator, would adversely affect participation in the study",{"count":356,"type":20},300,[55],"The purpose of this research study is to learn how to best provide weekly feedback on individual progress toward intervention goals during a weight loss program.",[27,360],"Obesity (Disorder)",[362,363,364,365,366,367,61,368,369,370,371],"weight loss","self-monitoring","smartphone app","lifestyle intervention","digital health","mHealth","dietary change","e-scale","wearables","activity monitor",{"date":373,"type":36},"2026-06-24",{"date":375,"type":36},"2026-01-26",{"date":377,"type":20},"2028-02-28",{"name":379,"class":43},"Wake Forest University Health Sciences",{"id":381,"slug":4,"hasResults":11,"nctId":382,"briefTitle":383,"officialTitle":384,"acronym":4,"eligibilityCriteria":385,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":106,"enrollmentInfo":386,"targetDuration":4,"studyType":21,"phases":388,"briefSummary":389,"conditions":390,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":392,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":44},"100644389","NCT07662330","Assessment of the Effects and Safety of Spermidine Supplementation on Blood Lipids and Body Weight in Overweight or Obese Individuals With Hyperlipidemia","Assessment of the Effects and Safety of Spermidine Supplementation on Blood Lipids and Body Weight in Overweight or Obese Individuals With Hyperlipidemia: A Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n* Males or females aged 18 to 65 years.\n* BMI ≥ 24 kg\u002Fm², without severe chronic diseases.\n* Not currently using glucose-lowering or lipid-lowering medications.\n* Dyslipidemia defined as triglycerides ≥ 1.7 mmol\u002FL or total cholesterol ≥ 5.2 mmol\u002FL.\n* No active weight loss or weight gain diet within the past 1 month.\n* No special dietary pattern changes (e.g., ketogenic, vegan, high-protein, meal replacement, intermittent fasting) within the past 1 month.\n* No use of supplements that may affect polyamine intake (e.g., germ, yeast, fermented extracts, nutritional powders) within the past 2-4 weeks.\n* Willing and able to provide signed informed consent.\n\nExclusion Criteria:\n\n* Diagnosis of acute or severe gastrointestinal disease\n* Concurrent participation in any other weight-loss therapy\n* Current use of hypoglycemic or lipid-lowering medications\n* Participation in any other clinical trial within one month prior to signing the informed consent form\n* Pregnancy, lactation, or planning a pregnancy during the trial period\n* Known allergy to cellulose or wheat\n* History of cancer\n* Renal insufficiency, indicated by abnormal serum creatinine levels\n* Hepatic impairment, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>3 × upper limit of normal (ULN), or total bilirubin (TBIL) \\>3 × ULN\n* Any other condition deemed by the investigator as inappropriate for trial participation",{"count":387,"type":20},50,[55],"Evaluate the effect of spermidine supplementation on lipid profile changes in individuals with overweight or obesity accompanied by hyperlipidemia. Analyze the impact of spermidine on metabolic parameters and assess the safety of spermidine supplementation, including liver and kidney function, gastrointestinal reactions, and other adverse effects.",[27,391],"Hyperlipidemia",{"date":342,"type":36},{"date":394,"type":36},"2026-01-01",{"date":396,"type":20},"2027-01-31",{"name":398,"class":43},"Shanghai 10th People's Hospital",{"id":400,"slug":4,"hasResults":11,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":4,"eligibilityCriteria":404,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":405,"targetDuration":4,"studyType":21,"phases":406,"briefSummary":407,"conditions":408,"keywords":410,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":414,"startDateStruct":415,"completionDateStruct":416,"leadSponsor":418,"locationsCount":44},"100624019","NCT07404189","Augmenting Primary Care-Based Obesity Management With the Nutu™ Digital Health Platform","Evaluation of the Acceptability and Clinical Effectiveness of Augmenting Comprehensive Primary Care-Based Obesity Management With the Nutu™ Digital Health Platform","Inclusion Criteria:\n\n* All patients enrolled in the FLOW clinical program are eligible.\n\nExclusion Criteria:\n\n* Not a patient of the FLOW clinical program at UAB.",{"count":356,"type":20},[55],"This study evaluates the acceptability and clinical effectiveness of integrating the Nutu™ digital health platform into a comprehensive primary care-based behavioral obesity treatment program using a Zelen randomized controlled trial design.",[27,409],"Cardiovascular Risk Factors",[411,412,413],"intensive behavioral therapy","digital health coaching","weight management",{"date":278,"type":36},{"date":227,"type":20},{"date":417,"type":20},"2028-06",{"name":349,"class":43},{"id":420,"slug":4,"hasResults":11,"nctId":421,"briefTitle":422,"officialTitle":423,"acronym":424,"eligibilityCriteria":425,"healthyVolunteers":105,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":426,"targetDuration":4,"studyType":21,"phases":428,"briefSummary":429,"conditions":430,"keywords":435,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":44},"100642489","NCT07638345","DASH-Obesity: Explainable AI for Family-Centric Personalized Weight Control in Adolescents and Young Adults With Obesity and Chronic Conditions","US-based Clinical Sub-study of DASH-Obesity: Explainable AI for Family-Centric Transdiagnostic Personalized Weight Control Across Multiple Conditions","DASH-Obesity","Inclusion Criteria:\n\n* Adult caregiver (aged 18 years or older) of an adolescent or young adult aged 12 to 21 years diagnosed with Type 1 Diabetes (T1D) or asthma.\n* The caregiver is actively involved in the management of the adolescent's or young adult's condition.\n* The adolescent or young adult must meet one of the following criteria:\n* T1D and normal weight (BMI between the 10th and 85th percentile), or\n* T1D and overweight\u002Fobesity (BMI ≥85th percentile), or\n* Asthma and overweight\u002Fobesity (BMI ≥85th percentile).\n* Willingness to participate in the Adhera Caring Digital Program-Obesity (ACDP-O).\n* Access to a smartphone or internet-enabled device compatible with the study application.\n* Willingness to provide self-reported information regarding the adolescent's or young adult's health status, including disease-related and anthropometric measures.\n* For caregivers of participants with T1D, willingness to share continuous glucose monitoring (CGM) information.\n\nExclusion Criteria:\n\n* Severe psychiatric or cognitive conditions that would interfere with participation in the digital intervention.\n* Current participation in another obesity- or chronic disease-related digital health intervention study.\n* Inability or unwillingness to comply with study procedures.\n* Refusal or inability to provide informed consent.",{"count":427,"type":20},280,[55],"This prospective single-arm feasibility study evaluates the Adhera Caring Digital Program for Obesity (ACDP-O), a family-centered digital health intervention designed to support adolescents and young adults with overweight\u002Fobesity and chronic conditions, including type 1 diabetes (T1D) and asthma. The intervention combines personalized educational content, wearable-device monitoring, psychometric assessments, and explainable artificial intelligence (AI) to improve mental well-being, quality of life, and adherence to healthy lifestyle behaviors. A total of 280 families will participate in a 3-month intervention with remote monitoring and follow-up assessments.",[277,431,27,432,433,434],"T1D","Obesity Type 2 Diabetes Mellitus","Asthma Acute","Asthma (Diagnosis)",[436,277,437,438,439,440,441,442,443,444,445,446],"Pediatric Obesity","Asthma","Overweight","Digital Health","Artificial Intelligence","Explainable AI","Caregiver Burden","Quality of Life","Mental Well-being","Wearable Devices","Family-Centered Care","2026-06-19",{"date":342,"type":36},{"date":450,"type":36},"2025-10-30",{"date":452,"type":20},"2026-09",{"name":454,"class":98},"Adhera Health, Inc.",{"id":456,"slug":4,"hasResults":11,"nctId":457,"briefTitle":458,"officialTitle":459,"acronym":460,"eligibilityCriteria":461,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":462,"targetDuration":4,"studyType":21,"phases":464,"briefSummary":465,"conditions":466,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":470,"completionDateStruct":471,"leadSponsor":473,"locationsCount":44},"100644045","NCT07667504","Dietary Approaches for the Management of Overweight and Obesity in Type 1 Diabetes","Dietary Approaches for the Management of Overweight and Obesity in Type 1 Diabetes: The D1ANA Study","D1ANA","Inclusion Criteria:\n\n* T1D treated with intensive insulin therapy (multiple daily insulin injections or continuous subcutaneous insulin infusion systems)\n* HbA1c 6.5-9%\n* BMI ≥ 25 and ≤ 45 kg\u002Fm2\n* Active prescription and use of CGM\n* Active prescription for glucagon\n\nExclusion Criteria:\n\n* Pregnancy, pregnancy planning, or breastfeeding\n* Forms of diabetes other than T1D, or T1D duration \\\u003C 1 year\n* Previous cardiovascular events (acute myocardial infarction or stroke), heart failure, unstable coronary artery disease, chronic kidney disease with estimated glomerular filtration rate ≤ 30 mL\u002Fmin\u002Fm², cirrhosis, or presence of active cancer\n* Unstable diabetes, episodes of glycemic decompensation (diabetic ketoacidosis) or severe hypoglycemia (level 3) within the past year.\n* Planned change in treatment during the study (switching from multiple daily insulin injections to continuous insulin infusion, or vice versa)\n* Use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, GLP-1\u002FGIP agonists, or other medications that may influence weight loss\n* Having experienced a change in body weight greater than 5% within the 3 months before screening\n* Following any form of diet prior to inclusion, carbohydrate restriction, or intermittent fasting\n* History of eating disorders or alcohol abuse\n* Inability to follow the dietary recommendations\n* Presence of other conditions that, in the investigator's judgment, may compromise participation in the study.",{"count":463,"type":20},75,[55],"Although type 1 diabetes (T1D) has traditionally been considered a disease associated with a lean phenotype, it is estimated that up to 2 out of 3 people living with T1D are overweight or obese, factors linked to an increased risk of complications in these patients. The available evidence regarding nutritional strategies for weight loss in T1D is very limited, and clinical trials are needed to determine how to effectively and safely promote weight loss in this population. In recent years, low-carbohydrate diets and several intermittent fasting protocols have demonstrated efficacy in promoting weight loss both in patients with type 2 diabetes and in patients with obesity without diabetes. In this study, we will evaluate the efficacy of moderate carbohydrate restriction, time-restricted eating, and standard calorie restriction for weight loss in adults with T1D and overweight\u002Fobesity.",[467,27],"Type 1 Diabetes (T1D)","2026-06-18",{"date":278,"type":36},{"date":67,"type":20},{"date":472,"type":20},"2028-07",{"name":474,"class":43},"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud",{"id":476,"slug":4,"hasResults":11,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":4,"eligibilityCriteria":480,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":481,"targetDuration":4,"studyType":21,"phases":482,"briefSummary":483,"conditions":484,"keywords":486,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":488,"startDateStruct":489,"completionDateStruct":490,"leadSponsor":492,"locationsCount":44},"100644231","NCT07666581","Influence of the Use of Specific Nutritional Formulas on Time in Range in Patients With Type 2 Diabetes","Influence of the Use of Specific Nutritional Formulas for Diabetes on Time in Range in Patients With Type 2 Diabetes Mellitus With Obesity by Freestyle Continuous Glucose Monitoring","Inclusion criteria:\n\n* Patients over 18 years of age.\n* Diagnosis of diabetes mellitus type 2.\n* HbA1c \\>7% to \\\u003C11%.\n* BMI \\>27 kg\u002Fmt2 \\\u003C35 kg\u002Fmt2\n* Current use of continuous glucose monitoring with adherence greater than 70%.\n* Access to technology to download data from CGM in a timely manner.\n* Ability to follow the study protocol and provide informed consent (Appendix 3).\n\nExclusion criteria:\n\n* Change in antidiabetic medication in the last 3 months.\n* Pregnancy or lactation or planning to become pregnant during the study period.\n* Acute decompensation of diabetes in the past 3 months.\n* Participation in another clinical trial.\n* Use of glucocorticoids or insulin in the past 3 months or planned use in the coming months.\n* Initiation of treatment with oral or injectable GLP-1 analogues 3 months prior to enrollment.\n* History of bariatric surgery or gastrointestinal pathology associated with malabsorption syndromes.",{"count":53,"type":20},[55],"Who can participate?\n\nIndividuals may be eligible to join this study if they meet the following criteria:\n\n* Are 18 years or older.\n* Have Type 2 diabetes with an A1c level higher than 7%.\n* Have a Body Mass Index (BMI) between 27 and 35 (considered overweight or Class 1 obesity).\n* Have used a continuous glucose monitor (CGM) successfully in the past.\n\nHow the study works:\n\nIf eligible individuals decide to join and sign the consent form, a computer will randomly assign them into one of two groups:\n\nThe Formula Group: Participants will replace their usual breakfast and one snack with a specific diabetes nutritional drink (Glucerna®).\n\nThe Standard Diet Group: Participants will follow a standard low-calorie meal plan without using the nutritional drink.\n\nBoth groups will aim for a specific daily calorie goal (1,200-1,500 for women; 1,500-1,800 for men) and will receive expert nutritional counseling.\n\nMonitoring and Follow-up\n\nOver the course of 3 months, close contact will be maintained to support participants:\n\nEvery 2 weeks: A nutrition expert will call participants to check on their diet and help with their glucose monitor.\n\nEvery month: Participants will meet with the study team in person to review glucose monitor data.\n\nTests: At the start and end of the study, weight, body composition, blood sugar (A1c), and cholesterol levels will be measured to see how the plans worked.",[222,27,485],"Time in Range",[222,198,487,485],"Continuos Glucose Monitoring",{"date":373,"type":36},{"date":227,"type":20},{"date":491,"type":20},"2028-12",{"name":493,"class":43},"Hospital Universitario San Ignacio",{"id":495,"slug":4,"hasResults":11,"nctId":496,"briefTitle":497,"officialTitle":498,"acronym":4,"eligibilityCriteria":499,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":106,"enrollmentInfo":500,"targetDuration":4,"studyType":21,"phases":501,"briefSummary":502,"conditions":503,"keywords":504,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":505,"startDateStruct":506,"completionDateStruct":508,"leadSponsor":510,"locationsCount":146},"100636828","NCT07570758","A Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity.","A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Clinical Study to Assess Efficacy, Safety and Tolerability of Orally Administered ERX1000 in Subjects With Obesity","Inclusion Criteria:\n\n1. Able to comprehend and willing to sign an ICF and to abide by the study requirements.\n2. Male and female subjects ages 18-60 years, inclusive.\n3. BMI \\>30 to \\\u003C50 kg\u002Fm2\n4. Stable body weight for 3 months (self-reported loss\u002Fgain \\\u003C5%).\n5. Stable diet and\u002For nutritional lifestyle for 3 months prior to randomization.\n6. If a subject has current diagnosis of prediabetes, the following criteria must be met:\n\n   1. Hemoglobin A1c (HbA1c) ≤6.4%\n   2. Fasting glucose ≤125 mg\u002FdL (≤6.94 mmol\u002FL)\n   3. No history of ketoacidosis or hyperosmolar coma\n7. Female subjects must not be pregnant or lactating. Nonpregnancy will be confirmed for all females by a urine pregnancy test conducted at Screening and at the Baseline Visit prior to enrollment into the study.\n\nIf of childbearing potential, the subject agrees to the use two of the following accepted contraceptive regimens from Screening to the first administration of the study drug, during the study, and for at least 30 days after the last dose of the study drug. Acceptable methods of contraception includes one of the following:\n\n1. Hormonal contraceptives (birth control pills, injectable\u002Fimplant\u002Finsertable hormonal birth control products, transdermal patch), OR\n2. Intrauterine device (with or without hormones), AND\n3. Agrees to use a barrier method (e.g., male or female condom) during the study and for at least 30 days after the last dose of the study drug.\n\nExclusion Criteria:\n\n1. Poorly controlled severe psychiatric disorders (e.g., bipolar disorder, or major depressive disorder), recent (within 6 months) psychotic episodes, history of suicide attempts or suicidal ideation, or any other psychiatric disorders that the Investigator believes will interfere significantly with study compliance.\n2. Lifetime history of DSM-5 diagnosis of schizophrenia or schizoaffective disorder. Diagnosis of bipolar 1 disorder within the previous 2 years.\n3. History of any bleeding disorders, deep vein thrombosis (DVT), or thromboembolic disease.\n4. Current liver, renal, pulmonary, cardiac, oncologic, or gastrointestinal (GI) disease including:\n\n   1. Significant cardiovascular disease including history of congestive heart failure (CHF), coronary artery disease, myocardial infarction (MI), second degree or greater heart block, prolonged time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole (QT) syndrome, or clinically significant arrhythmias.\n   2. Fridericia-corrected QT interval (QTcF) \\>460 msec for males and QTcF \\>480 msec for females pre-dose on Day 1.\n   3. Liver disease or liver function tests, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\>1.5 upper limit of normal (ULN), alkaline phosphatase (ALP) or serum bilirubin \\> ULN, or history of underlying liver disease including, hepatic cirrhosis, alcoholic hepatitis, or confirmed diagnosis of NASH; nonalcoholic fatty liver disease with qualifying LFTs will be allowed.\n   4. History or presence of impaired renal function as indicated by clinically significant abnormal creatinine, blood urea nitrogen (BUN), or urinary constituents or moderate to severe renal dysfunction as defined by the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation (\\\u003C60 mL\u002Fmin\u002F1.73m2).\n5. Type 1 diabetes mellitus or Type 2 diabetes mellitus or current or recent use of insulin (more than 1 week within 3 months prior to screening).\n6. Obesity induced by other endocrine disorders (e.g., Prader-Willi syndrome, Cushing's syndrome).\n7. Active autoimmune disease who are currently using or will likely require systemic glucocorticoid therapy in the next 6 months.\n8. Any previous surgical treatment or procedures with medical devices (such as insertion of lap band or gastric balloons) for obesity (excluding liposuction if performed \\> 1 year prior to screening).\n9. History of stomach or intestinal surgery or resection that would potentially alter absorption and\u002For excretion of orally administered drugs (uncomplicated appendectomy, cholecystectomy, and hernia repair \\> 6 months prior to Screening will be allowed).\n10. Uncontrolled endocrine disorders (e.g., Cushing syndrome, Addison's, Hashimoto's, hypothyroidism, hypogonadism).\n11. Clinically significant and abnormal screening hematology lab results or recurring infections, or if any of the following are observed regardless of the Investigator's assessment of clinical significance (laboratory tests may be repeated once for confirmation of out-of-range values):\n\n    1. Hemoglobin \\\u003C10 g\u002FdL (\\\u003C100 g\u002FL)\n    2. Absolute neutrophil count (ANC) \\\u003C2000\u002Fmm3\n    3. Platelets \\\u003C135 x 109\u002FL\n    4. ALT or AST \\> 1.5 ULN\n    5. GGT, ALP, total bilirubin, or INR \\> ULN\n12. Results of screening clinical laboratory tests (complete blood count \\[CBC\\] with differential and platelets, chemistry, and urinalysis profile) and electrocardiogram (ECG) outside normal range and considered to be clinically significant by the Investigator.\n13. Body weight of \\> 350 pounds (158.8 kilograms) due to weight limits of the DEXA scanner.\n14. Current use, or within the 30 days prior to screening, of the following atypical antipsychotic medications:\n\n    1. Olanzapine\n    2. Clozapine\n    3. Quetiapine\n15. Subjects on the following systemic concomitant medications who have not been on stable dose (or stable weight-based dose), defined as no more than ±25% variation in dose, for at least 3 months prior to study entry:\n\n    1. Vasopressin\n    2. Thyroid hormone\n    3. Testosterone\n    4. Other hormone or hormone replacement therapies\n    5. Anti-diabetes medications other than metformin (e.g., glucagon-like peptide-1 \\[GLP-1\\] receptor agonists, sodium-glucose linked transporter 2 (SGLT2) inhibitors, sulfonylureas)\n    6. Modafinil\n    7. Atypical anti-psychotics, other than those noted above\n    8. Anti-depressives\n    9. Attention deficit hyperactivity disorder (ADHD) medications\n16. Subjects on any prescription or over-the-counter anti-obesity agents in the 3 months prior to screening (e.g., Saxenda, Wegovy, Zepbound, Xenical, Acutrim, Qsymia, Adipex, compounded peptides).\n17. Chronic (\\>2 weeks) systemic glucocorticoid therapy (excluding topical, intraocular, intranasal, intra-articular, or inhaled preparations) within 1 month prior to study screening.\n18. Vital signs unstable, or with the following values:\n\n    1. Systolic blood pressure \\>160 mm Hg\n    2. Diastolic blood pressure \\>100 mm Hg\n    3. Pulse rate \\>100 beats per minute (bpm)\n19. Recent (within the last year) and\u002For recurrent history of autonomic dysfunction (e.g., unexplained syncope or palpitations).\n20. Current or anticipated chronic use (more than 2 days) of narcotics or opiates.\n21. Significant history of abuse of drugs or solvents in the year before screening, or history of alcohol abuse in the past year before screening or currently drinks in excess of 21 units or servings per week.\n22. Participation in any clinical study with an investigational drug\u002Fdevice within 3 months.\n23. Positive result for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) prior to initiation of dosing with study drug.\n24. Serious adverse reaction or hypersensitivity to any drug which the Investigator believes is clinically significant and relevant to study participation.\n25. Significant blood loss or blood donation \\>500 mL within 3 months.\n26. Females who are pregnant, nursing, or intend to become pregnant during the study.\n27. Subjects who are planning or likely to undergo surgery during the course of the study.\n28. Subject is, in the opinion of the Investigator, not suitable to participate in the study (e.g., clinically significant illness in the 8 weeks before screening; unable to commit to study visits, etc.).",{"count":129,"type":20},[83],"The primary objective is to assess the safety and tolerability of oral dose ERX1000 in obese subjects.",[27],[198],{"date":281,"type":36},{"date":507,"type":36},"2026-05-28",{"date":509,"type":20},"2027-05",{"name":511,"class":98},"ERX Pharmaceuticals",{"id":513,"slug":4,"hasResults":11,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":517,"eligibilityCriteria":518,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":519,"targetDuration":4,"studyType":21,"phases":521,"briefSummary":522,"conditions":523,"keywords":526,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":536,"startDateStruct":537,"completionDateStruct":539,"leadSponsor":541,"locationsCount":44},"100641477","NCT07661732","eHealth Lifestyle Intervention To Enhance Outcomes in HFpEF","Randomized Trial Of A Digital Lifestyle Education Strategy In Patients With Heart Failure And Overweight Or Obesity: The ELITE-HFpEF Study","ELITE-HFpEF","Inclusion Criteria:\n\n* Age over 18 years\n* Body mass index (BMI) over 27 kg\u002Fm²\n* Symptoms consistent with heart failure\n* Left ventricular ejection fraction (LVEF) of 50% or higher\n* Elevated NT-proBNP according to the European Society of Cardiology age-adjusted rule-in thresholds: 125 pg\u002FmL or higher if under 50 years, 250 pg\u002FmL or higher if 50 to 75 years, and 500 pg\u002FmL or higher if 75 years or older\n* Echocardiographic abnormalities: left ventricular hypertrophy, left atrial enlargement, or diastolic dysfunction\n\nExclusion Criteria:\n\n* Body mass index (BMI) over 40 kg\u002Fm²\n* Life expectancy of less than 1 year\n* Chronic kidney disease on renal replacement therapy\n* Moderate or greater valvular heart disease\n* Inability to exercise",{"count":520,"type":20},52,[55],"The goal of this clinical trial is to learn if a digital lifestyle education program improves exercise capacity in adults who have heart failure with preserved ejection fraction (HFpEF) and overweight or obesity. HFpEF is a type of heart failure in which the heart muscle is stiff and does not relax well, even though its pumping strength looks normal. The main questions it aims to answer are:\n\n* Does the program improve how much oxygen participants can use during exercise, a measure of fitness, after 6 months?\n* Does the program improve participants' quality of life and help them lose weight?\n\nResearchers will compare a group that uses the digital program plus usual care to a group that receives usual care alone. This will show whether the program adds a benefit.\n\nParticipants will:\n\n* Be placed by chance into one of the two groups\n* Use a study website with short videos on exercise, healthy eating, and managing stress (program group), with new content every week for 6 months\n* Have exercise tests, an ultrasound scan of the heart, blood tests, and complete a quality-of-life questionnaire at the start and after 6 months\n\nBoth groups will keep taking their usual heart failure medicines.",[524,27,525],"Heart Failure and Preserved Ejection Fraction","Heart Failure",[527,31,59,366,528,367,529,530,365,531,532,533,534],"HFpEF","eHealth","telemedicine","web-based intervention","cardiac rehabilitation","Mediterranean diet","cardiopulmonary exercise testing","quality of life","2026-06-16",{"date":281,"type":36},{"date":538,"type":20},"2026-09-01",{"date":540,"type":20},"2029-06-30",{"name":542,"class":43},"Maimónides Biomedical Research Institute of Córdoba",{"id":544,"slug":4,"hasResults":11,"nctId":545,"briefTitle":546,"officialTitle":547,"acronym":548,"eligibilityCriteria":549,"healthyVolunteers":105,"sex":16,"minAge":550,"maxAge":551,"enrollmentInfo":552,"targetDuration":4,"studyType":21,"phases":554,"briefSummary":555,"conditions":556,"keywords":560,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":576,"completionDateStruct":577,"leadSponsor":579,"locationsCount":44},"100641855","NCT07659028","Human Pilot Study for the Investigation of the Role of Bilberry and Olive Bioactives on Oxidative Stress Parameters and Inflammatory Markers.","A Blinded Placebo-controlled Human Pilot Study for the Investigation of the Role of Bilberry and Olive Bioactives on Oxidative Stress Parameters and Inflammatory Markers. Relevance in European Population","BIOTRANSFORM","Inclusion Criteria:\n\n* 30-50 years old,\n* BMI\\> 25 kg\u002Fm2\n* prediabetic stage\n* hsCRP\\> 2mg\u002F L\n* HbA1c 5,7-6,4%\n* Impaired fasting glucose (IFG)\n* Caucasian\n\nExclusion Criteria:\n\n* No signed informed consent\n* Supplementation or probiotic usage in the past 8 weeks\n* Chronic gastrointestinal, inflammatory or metabolic diseases\n* Alcohol misuse\n* Pregnancy or breastfeeding\n* Acute infection during the past month","30 Years","50 Years",{"count":553,"type":20},60,[55],"Numerous plant-based foods contain bioactive compounds, in particular polyphenols, which have antioxidant, anti-inflammatory, and metabolic regulatory effects. These so-called food bioactives (FB) are converted in the human organism, in particular by the gut microbiota and microsomal (liver\u002Fintestinal) metabolism, into numerous metabolites, which often represent the actual biologically active molecules. As part of the European HORIZON-MSCA Doctoral Network \"BioTransform,\" two such food models are being studied as examples: 1. Olive products (Olea europaea L.) - representative of the Mediterranean diet, rich in secoiridoids and phenylethanols (especially hydroxytyrosol and tyrosol). 2.\n\nBilberry \u002Fblueberry (Vaccinium myrtillus L.) - representative of the Central European diet, rich in anthocyanosides. Two parallel human intervention studies will be conducted, one in Graz (WP1, DC5) and one in Athens (WP1, DC3). These pilot studies will generate biological samples (blood, urine, stool) and investigate the extent to which taking these standardized dietary supplements influences glucose metabolism and markers of oxidative stress and low-grade inflammation.",[557,27,558,559],"Prediabetes","Inflamation","Oxidative Stress",[561,562,563,564,565,566,567,568,569,570,571,572,573],"FOOD BIOACTIVES","FOOD BIOACTIVE COMPOUNDS","OLIVE PRODUCTS","BILBERRY PRODUCTS","OLEA EUROPEA L.","BILBERRY","VACCINUM MYRTILLOUS L.","GUT MICROBIOME","MICROBIOME MAPPING","IN VITRO","IN SILICO","BIOACTIVE COMPOUNDS","METABOLISM","2026-06-15",{"date":281,"type":36},{"date":91,"type":20},{"date":578,"type":20},"2029-10-31",{"name":580,"class":43},"National and Kapodistrian University of Athens",{"id":582,"slug":4,"hasResults":11,"nctId":583,"briefTitle":584,"officialTitle":585,"acronym":586,"eligibilityCriteria":587,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":106,"enrollmentInfo":588,"targetDuration":4,"studyType":156,"phases":4,"briefSummary":589,"conditions":590,"keywords":592,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":599,"startDateStruct":600,"completionDateStruct":602,"leadSponsor":604,"locationsCount":179},"100641833","NCT07650149","Genetic, Microbiological and Behavioral Factors in Obesity","OPTIMIZE GEN - Outcomes of Persistence and Treatment With tIrzepatide deterMined by Genetic, mIcrobiological & bEhavioral Factors in obEsity","OPTIMIZE-GEN","Inclusion criteria\n\n* Age 18-60 years\n* Consent to participate in the study and providing informed written consent\n* Overweight or obese with a BMI \\>27\n\nExclusion criteria\n\n* Contraindications to tirzepatide use:\n* Type 1 or type 2 diabetes\n* Pregnancy or breastfeeding\n* Cancer\n* Heart failure\n* Expected lack of patient compliance\n* Taking immunosuppressive medications, steroids, NSAIDs, antibiotics (within 2 weeks prior to sample collection),\n* Autoimmune and inflammatory diseases, acute infectious diseases, AIDS, tuberculosis\n* Mental illness\n* Alcohol dependence syndrome\n* Liver cirrhosis\n* Post-myocardial infarction or stroke",{"count":81,"type":20},"This study will assess the impact of genetic markers, microbiological (microbiome) and behavioral factors on tolerance, adherence and effectiveness of dual GLP1\u002FGIP RA in the treatment of obesity.\n\n200 consecutive patients who meet all inclusion and none of the exclusion criteria will be enrolled.",[27,198,591],"Genetics",[593,31,594,595,596,597,598],"tirzepatide","genetics","microbiom","adherence","compliance","gene",{"date":535,"type":36},{"date":601,"type":36},"2026-05-23",{"date":603,"type":20},"2028-05",{"name":605,"class":43},"Jan Kochanowski University",{"id":607,"slug":4,"hasResults":11,"nctId":608,"briefTitle":609,"officialTitle":610,"acronym":4,"eligibilityCriteria":611,"healthyVolunteers":11,"sex":239,"minAge":17,"maxAge":612,"enrollmentInfo":613,"targetDuration":4,"studyType":21,"phases":615,"briefSummary":616,"conditions":617,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":618,"startDateStruct":620,"completionDateStruct":622,"leadSponsor":624,"locationsCount":179},"100642183","NCT07652047","A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets","A Phase 1b Study Investigating Safety, Pharmacokinetics, and Pharmacodynamics of CX11 Tablets in Participants With Obesity or Overweight With Weight-Related Comorbidities","Inclusion Criteria:\n\n* Male or female, 18-55 years.\n* BMI ≥30.0 to ≤39.9 kg\u002Fm², or ≥27.0 to \\\u003C30.0 kg\u002Fm² with at least 1 weight-related comorbidity: prediabetes, hypertension, dyslipidemia, or obstructive sleep apnea.\n* Prior unsuccessful diet\u002Fexercise weight-loss attempt and stable body weight within 90 days.\n* Able to comply with study procedures and reproductive requirements.\n\nExclusion Criteria:\n\n* Diabetes or obesity due to endocrine\u002Fgenetic causes.\n* Recent weight-loss drugs, GLP-1-based therapy, glucose-lowering drugs, obesity surgery\u002Fdevice, or investigational treatment.\n* Significant cardiovascular, ECG\u002FQT, pancreatic, gallbladder, GI, liver, kidney, thyroid, psychiatric, malignant, infectious, autoimmune, or lab abnormality risks.\n* Personal\u002Ffamily history of medullary thyroid carcinoma or multiple endocrine neoplasia.\n* Pregnancy, breastfeeding, recent nicotine\u002Fdrug use, excessive alcohol use, or any condition\u002Fmedication making participation inappropriate.","55 Years",{"count":614,"type":20},90,[268],"A multi-center, randomized, placebo-controlled, double-blinded (within cohorts), Sponsor-unblinded, Phase 1b study to explore the safety, pharmacokinetics, and pharmacodynamics of CX11 tablets in participants with obesity or overweight with weight-related comorbidities.",[27],{"date":619,"type":36},"2026-06-17",{"date":621,"type":36},"2026-05-11",{"date":623,"type":20},"2027-06",{"name":625,"class":98},"Corxel Pharmaceuticals",{"id":627,"slug":4,"hasResults":11,"nctId":628,"briefTitle":629,"officialTitle":630,"acronym":4,"eligibilityCriteria":631,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":632,"targetDuration":4,"studyType":21,"phases":634,"briefSummary":635,"conditions":636,"keywords":638,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":643,"lastUpdatePostDateStruct":644,"startDateStruct":645,"completionDateStruct":647,"leadSponsor":648,"locationsCount":44},"100641299","NCT07657676","Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity","Effect of Mazdutide on Coronary Plaque Progression in Patients With Coronary Atherosclerosis and Overweight or Obesity: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. BMI ≥ 28 kg\u002Fm2 or BMI≥ 24kg\u002Fm2 with at least one of the following conditions: dyslipidemia, metabolic associated fatty liver disease, hypertension, prediabetes, type 2 diabetes mellitus, or obesity-related obstructive sleep apnea syndrome (at screening or within 6 months prior to screening).\n3. Coronary stenosis 30-70% confirmed by CAG or CCTA\n4. Signed informed consent\n5. Willing to comply with follow-up\n\nExclusion Criteria:\n\n1. History or evidence of the following :\n\n   1. A history of severe hypoglycemia, or recurrent symptomatic hypoglycemia (≥2 episodes) within the past six months\n   2. Severe heart disease as determined by the investigator, including coronary artery disease that has undergone or is planned for coronary artery bypass grafting or percutaneous coronary intervention, valvular heart disease requiring valve repair or replacement, heart transplantation, severe heart failure (NYHA III-IV) or cardiogenic shock, or a known history of left ventricular ejection fraction ≤30%\n   3. A hemorrhagic\u002Fischemic stroke or transient ischemic attack within six months prior to screening\n   4. A history of acute or chronic pancreatitis, gallbladder\u002Fbile duct disease, or pancreatic injury\n   5. Presence of severe diseases such as malignant tumors, lymphoma, liver cirrhosis, HIV-positive status, etc., with an expected survival of less than 2 years\n   6. Contraindications to GLP-1\u002FGCG dual receptor agonists, such as hypersensitivity or severe intolerance\n   7. A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2\n2. Use of the following medications or treatments prior to screening :\n\n   1. Use of weight-affecting medications (e.g., systemic steroids, tricyclic antidepressants, psychiatric\u002Fsedative medications, etc.) within three months prior to screening\n   2. Use of GLP-1 RA or GIP\u002FGLP-1 RA (exposure to investigational drugs) within three months prior to screening\n   3. Participation in other clinical trials (exposure to investigational drugs) within three months prior to screening\n   4. Known clinically significant abnormal gastric emptying or current use of medications that directly affect gastrointestinal motility\n3. Laboratory test results meeting any of the following criteria at screening (repeat testing within one week is permitted if there is a clear reason, and the reason for retesting must be documented by the investigator)\n\n   1. Serum calcitonin ≥50 ng\u002FL (pg\u002FmL)\n   2. ALT\u002FAST \\>3.0 × ULN\n   3. eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²\n   4. Abnormal thyroid function (TSH \\>6 mIU\u002FL or \\\u003C0.4 mIU\u002FL)\n4. Pregnancy, planned pregnancy, or breastfeeding\n5. Contraindications to CCTA, including severe allergy to iodine contrast agents, presence of cardiac implantable electronic devices or other metal implants that may affect image analysis\n6. Inability to complete the study or comply with study requirements as determined by the investigator Exclusion criteria for the PET-CT substudy: All exclusion criteria of the main study, as well as contraindications to PET-CT examination",{"count":633,"type":20},116,[23],"This multicenter, randomized, double-blind, placebo-controlled trial aims to evaluate the effect of mazdutide, a dual GLP-1\u002FGCG receptor agonist, on coronary plaque progression assessed by coronary computed tomography angiography (CCTA) in patients with coronary atherosclerosis and overweight or obesity. The primary endpoint is the change in total non-calcified plaque volume (NCPV) from baseline to week 52. Secondary endpoints include changes in pericoronary adipose tissue inflammation (fat attenuation index, FAI), plaque composition, metabolic parameters, inflammatory biomarkers, and clinical outcomes. A substudy will include 18F-NAF PET\u002FCT imaging.",[27,637],"Coronary Heart Disease",[639,640,641,198,642,438,637],"GLP-1RA","CCTA","Mazdutide","Plaque","2026-06-14",{"date":468,"type":36},{"date":646,"type":20},"2026-05-25",{"date":377,"type":20},{"name":649,"class":650},"China National Center for Cardiovascular Diseases","OTHER_GOV",""]